Gwee M C
Ann Acad Med Singap. 1985 Jan;14(1):95-103.
Major differences exist in the pharmacokinetic profile of the benzodiazepines and this provides a clinically useful basis for the therapeutic selection of compounds, particularly as anxiolytics and hypnotics. There are important differences in the elimination profile of the benzodiazephines: several factors can modify the process of oxidation appreciably; the plasma elimination half-life (T 1/2 beta) and the residual fraction (r12,1; R1, rSS) are useful pharmacokinetic parameters for evaluating the potential for persistent residual CNS depressant effects. Differences in the onset-time and duration of action are also influenced by the absorption and distribution profiles of the compounds.
苯二氮䓬类药物的药代动力学特征存在重大差异，这为化合物的治疗选择提供了临床有用的依据，尤其是作为抗焦虑药和催眠药。苯二氮䓬类药物的消除特征存在重要差异：几个因素可显著改变氧化过程；血浆消除半衰期（T 1/2β）和残留分数（r12,1；R1，rSS）是评估持续性残留中枢神经系统抑制作用可能性的有用药代动力学参数。作用起效时间和持续时间的差异也受化合物吸收和分布特征的影响。
